Aligos Therapeutics annual revenue
2020
2021
2022
2023
2024
2025
Aligos Therapeutics Revenue Growth & History (ALGS)
Aligos Therapeutics reported $2.2M in revenue for fiscal 2025, a decrease of 39.46% from the previous fiscal year.
View full Aligos Therapeutics company overviewAligos Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.2M | −$1.4M | −39.46% |
| 2024 | 2024-12-31 | $3.6M | −$2.6M | −41.67% |
| 2023 | 2023-12-31 | $6.2M | $6.2M | — |
| 2022 | 2022-12-31 | $0 | $0 | — |
| 2021 | 2021-12-31 | $0 | $0 | — |
| 2020 | 2020-12-31 | $0 | — | — |
Aligos Therapeutics quarterly revenue
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$965,000 | −100.00% |
| Q1 2026 | 2026-03-31 | $2.8M | $2.5M | +809.97% |
| Q4 2025 | 2025-12-31 | $169,000 | −$437,000 | −72.11% |
| Q3 2025 | 2025-09-30 | $741,000 | −$509,000 | −40.72% |
| Q2 2025 | 2025-06-30 | $965,000 | −$96,000 | −9.05% |
| Q1 2025 | 2025-03-31 | $311,000 | −$383,000 | −55.19% |
| Q4 2024 | 2024-12-31 | $606,000 | −$66,000 | −9.82% |
| Q3 2024 | 2024-09-30 | $1.3M | $165,000 | +15.21% |
| Q2 2024 | 2024-06-30 | $1.1M | −$3.2M | −75.29% |
| Q1 2024 | 2024-03-31 | $694,000 | $554,000 | +395.71% |
| Q4 2023 | 2023-12-31 | $672,000 | — | — |
| Q3 2023 | 2023-09-30 | $1.1M | $1.1M | — |
| Q2 2023 | 2023-06-30 | $4.3M | $4.3M | — |
| Q1 2023 | 2023-03-31 | $140,000 | — | — |
| Q3 2022 | 2022-09-30 | $0 | — | — |
| Q2 2022 | 2022-06-30 | $0 | — | — |
Aligos Therapeutics revenue growth trends
Aligos Therapeutics's latest reported quarter, Q2 2026, generated $0 in revenue, a decrease of 100.00% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Aligos Therapeutics source filings ↗